Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired emotion recognition is associated with sleep-related hypoxic burden.

Sleep·2026
Same author

Reinventing amlodipine.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Emerging technologies and scientific advances in lyophilization of pharmaceuticals: insights from the 2025 freeze-drying of pharmaceuticals & biologicals conference.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Inflammasome adaptor ASC promotes sustained neuroinflammation and mild cognitive impairment in a closed-head injury model.

The Journal of clinical investigation·2026
Same author

Behavioral interventions as treatment for insomnia - A scoping review of randomized controlled trials.

Sleep medicine·2025
Same author

A novel mobile application to examine impaired vigilance through digital means.

Scientific reports·2025

Related Experiment Video

Updated: Oct 7, 2025

Using Touch-evoked Response and Locomotion Assays to Assess Muscle Performance and Function in Zebrafish
09:40

Using Touch-evoked Response and Locomotion Assays to Assess Muscle Performance and Function in Zebrafish

Published on: October 31, 2016

13.1K

Motility phenotype in a zebrafish vmat2 mutant.

Hildur Sóley Sveinsdóttir1, Amanda Decker2, Christian Christensen1

  • 13Z, Reykjavik, Iceland.

Plos One
|January 5, 2022
PubMed
Summary

Researchers developed a novel zebrafish model for Parkinson's disease by studying a mutation in the vesicular monoamine transporter 2 (vmat2). This model shows altered movement and sleep, offering a new tool for drug discovery.

More Related Videos

Analysis of Skeletal Muscle Defects in Larval Zebrafish by Birefringence and Touch-evoke Escape Response Assays
08:01

Analysis of Skeletal Muscle Defects in Larval Zebrafish by Birefringence and Touch-evoke Escape Response Assays

Published on: December 13, 2013

8.1K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.9K

Related Experiment Videos

Last Updated: Oct 7, 2025

Using Touch-evoked Response and Locomotion Assays to Assess Muscle Performance and Function in Zebrafish
09:40

Using Touch-evoked Response and Locomotion Assays to Assess Muscle Performance and Function in Zebrafish

Published on: October 31, 2016

13.1K
Analysis of Skeletal Muscle Defects in Larval Zebrafish by Birefringence and Touch-evoke Escape Response Assays
08:01

Analysis of Skeletal Muscle Defects in Larval Zebrafish by Birefringence and Touch-evoke Escape Response Assays

Published on: December 13, 2013

8.1K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.9K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Parkinson's disease is a neurodegenerative disorder affecting dopamine-producing neurons.
  • Vesicular monoamine transporter 2 (vmat2) plays a crucial role in neurotransmitter packaging and transport.
  • Zebrafish offer a valuable model system for studying neurological disorders due to their genetic tractability and optical transparency.

Purpose of the Study:

  • To characterize a novel zebrafish mutant of solute carrier 18A2 (slc18a2), also known as vesicular monoamine transporter 2 (vmat2).
  • To investigate the behavioral and neurochemical phenotypes of this vmat2 mutant.
  • To assess the potential of this model for high-throughput drug screening for Parkinson's disease therapeutics.

Main Methods:

  • Generation and characterization of a slc18a2 (vmat2) zebrafish mutant.
  • Behavioral analysis using photomotor assays, including response to light/dark stimuli and thigmotaxis.
  • Assessment of dopamine cell number and rescue experiments with pramipexole, L-Dopa, and GDNF.

Main Results:

  • The vmat2 mutant larvae exhibited altered motility, with increased initial movement upon lights-off but reduced subsequent inhibition, and hypomotility during lights-on periods.
  • Mutant larvae displayed increased thigmotaxis and a higher daytime sleep ratio compared to wild-type and heterozygous siblings.
  • Pharmacological treatment with pramipexole or L-Dopa, and GDNF injection, partially rescued the observed motor deficits.

Conclusions:

  • The novel vmat2 zebrafish mutant displays behavioral and neurochemical phenotypes partially mirroring human Parkinson's disease.
  • This model serves as a valuable tool for high-throughput screening of potential therapeutics targeting monoamine transport.
  • Further studies using this model can elucidate the function of monoamine transporters in neurological health and disease.